Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT) with high mortality rate. We retrospectively studied the frequency, clinical and genetic associations and prognostic effect of TA-TMA, in a total of 425 consecutive adult patients, who underwent allo-HSCT for a malignant haematological condition between 2007 and 2013 at our single centre. TA-TMA developed in 19% of the patients. Unrelated donor type (P o 0.001), acute GvHD grades II-IV (P o0.001), myeloablative conditioning regimens (P = 0.003), tacrolimus-based GvHD prophylaxis (P = 0.003), CMV infection (P = 0.003) and carriership for HLA-DRB1*11 (P = 0.034) were associated with the development of TA-TMA. Survival was adversely affected by the presence of TA-TMA (P o 0.001). Among patients with TA-TMA, the outcome of HLA-DRB1*11 carriers was significantly better compared with non-carriers (P = 0.003). As a new finding, our observations suggest that the presence of HLA-DRB1*11 antigen contributes to the development of TA-TMA and affects the outcome.
INTRODUCTION
Allogeneic haematopoietic stem cell transplantation (HSCT) can offer long-term survival benefit by eradicating malignancy, although it confers a considerable risk of treatment-related mortality. Transplantation-associated thrombotic microangiopathy (TA-TMA) is a well-documented complication of HSCT with high mortality rate (~30-80%).
1 Although the exact pathophysiology remains unclear, endothelial dysfunction with platelet activation and formation of platelet-rich thrombi in the microcirculation are regarded as key elements, leading to platelet consumption, mechanical damage to red blood cells and secondary organ damage.
2, 3 The role of predisposing risk factors has been addressed, 2,4-6 such as female gender, 7, 8 older age, 9,10 lymphoid malignancy, 11 unrelated donor, 7, 10 HLA mismatch, 9 conditioning and immunosuppressive regimens, 7, [10] [11] [12] [13] [14] [15] [16] infections, 3, 9, 11, 17 acute GvHD (aGvHD) 7, [10] [11] [12] 17, 18 and ABO incompatibility. 19 Acquired idiopathic thrombotic thrombocytopenic purpura (TTP) also belongs to the family of thrombotic microangiopathies. In most cases, TTP is attributed to an autoimmune deficiency of the von Willebrand factor-cleaving protease, known as ADAMTS13, leading to intravascular thrombus formation. 20 Therapeutic plasma exchange (TPE) significantly changed the course of TTP and decreased the mortality from 85-95% to 10-20%. 20 TPE restores ADAMTS13 activity via replacement of the deficient protein and removal of autoantibodies. 20 TA-TMA is a multifactorial disorder secondary to a variety of insults, but not associated with severe ADAMTS13 deficiency. 20 TPE is proved to be a less efficient therapeutic modality in TA-TMA.
1,21
Despite aetiologic differences, TTP and TA-TMA share several clinical and histological similarities. The presentation might be indistinguishable with hallmarks of microangiopathic haemolytic anaemia and thrombocytopenia with secondary renal and/or neurological dysfunction. In recent years, an association of HLA-DRB1*11 and idiopathic TTP has been recognised by independent groups. [22] [23] [24] Our hypothesis was that in view of the correlations between the two conditions, HLA-DRB1*11 might have a role in the pathogenesis of TA-TMA, as well.
MATERIALS AND METHODS Patients
Data from 425 consecutive adult patients, undergoing first allogeneic HSCT for a malignant haematological condition between January 2007 and December 2013 at our transplant centre were retrospectively reviewed. Conditioning and post-transplantation immunosuppressive regimens for GvHD prevention were employed dependent on disease indication, donor availability, patients' comorbidities and other variables. aGvHD was defined and graded according to consensus criteria. 25 For post-transplantation immunosuppression, cyclosporine, tacrolimus (TAC) and sirolimus were routinely applied. Our definition of TA-TMA was based on the following probable TMA criteria proposed by Cho et al: (1) ⩾ 2 schistocytes per high-power field; (2) increased serum lactate dehydrogenase; (3) de novo thrombocytopenia ( o50 × 10 9 l − 1 ) or a decrease in platelet count of ⩾ 50%; (4) reduced haemoglobin; (5) absence of coagulopathy; and (6) negative Coombs' test. 9 To distinguish more severe cases within TA-TMA by Cho's definition, patients also fulfilling all criteria of the Blood and Marrow Transplant Clinical Trials Network recommendations, showing signs of organ involvement were categorised as TA-TMA with organ damage. 26 TA-TMA treatment focused on the elimination and aggressive management of triggers, such as medications (by dose reduction or regimen change), infections and aGvHD. A small minority of patients were treated with TPE. The study was approved by the Hungarian National Ethics Committee. Informed consent was obtained from all patients.
HLA typing
In the sibling donor setting, HLA-A, -B and -DRB1 typing for recipients and donors were performed with low resolution by PCR sequence-specific primers (Olerup, Stockholm, Sweden) or PCR sequence-specific oligonucleotides (One Lambda, Los Angeles, CA, USA). In the unrelated setting, high-resolution (4 digits) HLA typing was performed for HLA-A, -B, -C, -DRB1 and -DQB1 by high-resolution sequence-specific primer (Olerup) or sequence-based typing (Qiagen, ROSE, Valencia, CA, USA). In the whole cohort, two patients underwent allogeneic HSCT with HLA-DRB1 mismatched donor based on high-resolution typing, both patients and their donors carried HLA-DRB1*11 (although not the same allele), therefore we included these patients in the analysis.
Statistical methods
To assess factors associated with the development of TA-TMA, categorical variables were analysed using the χ2 or the Fisher's exact tests, whereas continuous variables by Mann-Whitney test. Overall survival (OS, defined as survival from the day of transplant until death or last follow-up) was estimated by Kaplan-Meier curves and the log-rank test was performed. Parameters with a P-value below 0.1 in univariate analyses were included in the Cox proportional hazard model. Cumulative incidence of TA-TMA was calculated by the Fine and Gray model, with death as a competing risk. 27 The analyses were carried out with SPSS Statistics 22 (Armonk, NY, USA) and STATA10 software (College Station, TX, USA).
RESULTS
Predicting factors for the development of TA-TMA TA-TMA developed in 18.8% of the patients (80/425), among them 41 patients showed organ damage (51.3% of all TA-TMA patients).
The median time to develop TA-TMA from the day of transplant was 40 days (range 6-1670 days) and in 81% of patients the diagnosis was made within the first 100 days of transplantation.
As a first step, clinical factors previously reported to associate with TA-TMA were tested (Supplementary Table 1 ) and factors significantly associated with TA-TMA are listed in Table 1 . TA-TMA developed in 27.4% of patients with an unrelated donor in contrast to 10.6% of those with a sibling donor (Po 0.001). The incidence of TA-TMA doubled in myeloablative conditioning (MAC) compared with reduced intensity conditioning (23.2% vs 11.4%, P = 0.003). High TA-TMA incidence (32.2%) was observed when high-dose busulfan (16 mg/kg) was a part of the conditioning regimen (P = 0.007 and P = 0.08 when compared with all other regimens and other MAC regimens, respectively). In the cyclosporine-based prophylactic subgroup, TA-TMA was diagnosed in 9%, whereas the frequency of TA-TMA was greater when TAC was administered (21.8%, P = 0.003), irrespectively of other agents given in combination (with sirolimus: 22.1%; with mycofenolate mofetil or methotrexate: 21.0%). Although 7.8% of patients without aGvHD manifested with TA-TMA, 35.2% and 55.0% were diagnosed among those who had a grade II or grade IV aGvHD, respectively. CMV (reactivation/disease) was also found to be a risk factor for TMA (P = 0.003). Age, recipient's gender, recipient and donor gender matching, diagnosis as lymphoid or myeloid malignancy and ABO incompatibility did not show any association with the development of TA-TMA.
In addition, we observed that HLA-DRB1*11 was significantly associated with the development of TA-TMA with a frequency of 24.8% (n = 34) in DRB1*11-positive cases vs 16% (n = 46) in DRB1*11-negative cases (P = 0.034 in univariate analyses). The development of organ damage was not different in HLA-DRB1*11 positive (44%; 15/34) and in HLA-DRB1*11 negative (56%; 26/46; P = 0.366) TA-TMA patients. The cumulative incidence of TA-TMA according to HLA-DRB1*11 status was significantly different, with Abbreviations: CMV = cytomegalovirus; CSA = cyclosporine; HSCT = haematopoietic stem cell transplantation; MAC = myeloablative conditioning; NA, not applicable; RIC = reduced intensity conditioning; TAC = tacrolimus; TA-TMA = transplantation-associated thrombotic microangiapathy.
HLA-DRB1*11 in post-transplantation microangiopathy K Balassa et al death calculated as a competing risk in the analyses (P = 0.026; Figure 1 ). In multivariate analyses, the association of TMA with donor type and grades II-IV aGvHD was independently significant, HLA-DRB1*11 and CMV showed a tendency, while the rest failed to remain significantly related (Table 2) . HLA-DRB1*11 was the commonest DRB1 antigen in the cohort with a carrier frequency of 32.2% (127 heterozygous and 10 homozygous recipients). This frequency was comparable to that of the Hungarian National Stem Cell Donor Registry (28.2%). The baseline characteristics were not different comparing HLA-DRB1*11 carriers with non-carriers except for donor type (HLA-DRB1*11 carrier frequency in unrelated donor HSCT: 38.9%, whereas in sibling donor HSCT: 25.8%, P = 0.005, Supplementary Table 2 ). The HLA-DRB1*11 carrier frequency in unrelated donor HSCT was significantly higher compared with the Hungarian registry (P = 0.001), whereas in the sibling setting data were similar (P = 0.5). As we observed altered distribution of donor type, we analysed separately TA-TMA occurrence according to HLA-DRB1*11 status in sibling and unrelated donor type groups. HLA-DRB1*11 carriership influenced the emergence of TA-TMA in the sibling group (17.8% (10/56) in HLA-DRB1*11-positive cases vs 8.1% (13/161) in HLA-DRB1*11-negative cases; P = 0.047), but not in the unrelated donor group (29.6% (24/81) in HLA-DRB1*11-positive cases vs 26.0% (33/127) in HLA-DRB1*11-negative cases; P = 0.633).
Predicting factors for the survival of TA-TMA patients The median follow-up for surviving patients (51% of all patients) was 36 months (range 6-92 months). The OS of patients with TA-TMA was significantly worse compared with patients without this complication (36-month OS: 27.4 ± 5.3% vs 55.3 ± 2.9%; P o0.001, Figure 2a) . In multivariate analyses, the development of TMA was an independent adverse risk factor affecting survival (hazard ratio 1.9, 95% confidence interval: 1.35-2.62), considering age, donor type and aGvHD grades III-IV, as covariates.
HLA-DRB1*11 did not influence OS in the whole cohort. Interestingly, although the survival of patients not affected by TA-TMA was not influenced by HLA-DRB1*11, carriers of this antigen showed superior OS among all TA-TMA patients (P = 0.003, Figure 2b ). In TA-TMA, carriership of HLA-DRB1*11 was an Abbreviations: CI = confidence interval; CMV = cytomegalovirus; CSA = cyclosporine; MAC = myeloablative conditioning; MUD = matched unrelated donor; OR = odds ratio; RIC = reduced intensity conditioning; TAC = tacrolimus. Factors with a P-value below 0.1 in univariate analyses were included in the multivariate analysis. HLA-DRB1*11 in post-transplantation microangiopathy K Balassa et al independent predictor of survival (hazard ratio: 0.46, 95% confidence interval: 0.27-0.81, P = 0.007), together with grades III-IV aGvHD (hazard ratio: 1.8, 95% confidence interval: 1.07-3.14, P = 0.027).
DISCUSSION
To our knowledge, this is the first study examining the association between TA-TMA and HLA-DRB1*11 in addition to providing information on multiple other risk factors. Our observations suggest that HLA-DRB1*11 predisposes for TA-TMA and influences survival of TA-TMA affected patients. The exact definitions of TA-TMA are not settled. 1 Therefore, reported data show enormous variations in terms of incidence (0-75%), risks and mortality. [4] [5] [6] 28 In a review of 35 reports from 2004, 28 different definitions were documented. 4 Attempts were made towards the harmonisation of the diagnosis and the application of the following three diagnostic criteria were suggested: Blood and Marrow Transplant Clinical Trials Network (2005), 26 International Working Group (2007) 29 and probable TMA (2010). 9 The limitations of these recommendations were also explored. 3, 9, 30 In the current study, we applied two of the above criteria. 9, 26 In 2014, an international panel suggested updated diagnostic guidelines.
1, 31 In our study, the adaptation of the proposed criteria was limited by the lack of serum complement C5b-9 measurements.
In our cohort, TA-TMA occurred in 18.8% of patients with a predominant presentation in the early post-transplant period similar to previous studies. 1 In agreement with earlier reports, several risk factors for TA-TMA were found, such as unrelated donor type, aGvHD, MAC, TAC-based immunosuppression, CMV and, as a new finding, HLA-DRB1*11. In good agreement with the literature, one of the strongest predictors for TA-TMA was aGvHD grades II-IV. 5, 7, 10, 11, 18, 32 The role of calcineurin inhibitors and mammalian target of rapamycin inhibitors in the pathogenesis is well established.
2-4 Several publications indicated that the risk of TA-TMA was substantially higher with the combination of TAC and sirolimus. [13] [14] [15] In our cohort, no higher risks with TAC and sirolimus combinations were observed compared with other TAC-containing regimens, in line with findings of Labrador et al. 11 With regards to conditioning intensity, reports demonstrate controversial results. 2, 5, [10] [11] [12] In this study, we detected an increased risk of TA-TMA, when MAC was applied. However, our observations may be biased, because TAC-based immunosuppression was administered almost exclusively in the MACtreated subgroup (93% vs 48% in reduced intensity conditioning). The contribution of infections to TA-TMA appearance was implicated. 3, 11, 17 Like earlier reports, we found an increased TA-TMA incidence in patients with CMV reactivation/disease. Unlike some data, 2,7,8,11,19 we could not identify significant associations of female gender, lymphoid malignancies or ABO incompatibility with TA-TMA.
As a novel finding, our data show that HLA-DRB1*11 also has a role in the development of TA-TMA. Together with previous reports, our findings suggest that, HLA-DRB1*11 is related to syndromes of thrombotic microangiopathy, including TTP, [22] [23] [24] haemolytic uraemic syndrome 33 and TA-TMA. The observed association of HLA-DRB1*11 and TA-TMA indicate that the role of HLA-DRB1*11 in the pathogenesis of thrombotic microangiopathies might be complex and extend beyond susceptibility to autoantibody formation against ADAMTS13. The association of HLA-DRB1*11 was documented with certain autoimmune, infectious and malignant conditions such as systemic sclerosis, Henoch-Schönlein purpura, Helicobacter pylori-positive idiopathic thrombocytopenic purpura, hairy cell leukaemia, cervical cancer and others. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Interestingly, in hairy cell leukaemia, anti-CD22 recombinant immunotoxin BL22-induced haemolytic uraemic syndrome (another, not ADAMTS13 deficiency-associated form of TMA) was also associated with HLA-DRB1*11. 33 The wide clinical spectrum of HLA-DRB1*11-associated conditions advocate the co-occurrence of additional provoking factors, because a unique mechanism is unlikely to drive all the above mentioned conditions. In the presence of a predisposing genetic background (such as HLA-DRB1*11), less robust acquired components might induce TA-TMA.
We observed a higher proportion of HLA-DRB1*11 carriers in the unrelated setting, which may be explained by the fact that HLA-matched donor selection is more successful for HLA-DRB1*11 recipients being the most frequent HLA-DRB1 allele. To overcome the above bias, subgroup analysis for sibling patients was performed indicating the association of HLA-DRB1*11 with TA-TMA, but not in the unrelated donor subgroup. In unrelated donor transplantation, the role of a genetic factor, such as HLA-DRB1*11, might be overcome by other stronger hereditary and acquired variables.
In the case of TA-TMA patients, the survival of HLA-DRB1*11 carriers was surprisingly better compared with non-carriers. Taking into consideration that in TTP a very strong association with HLA-DRB1*11 was confirmed in several studies, and TTP has an extremely poor prognosis without therapeutic plasma exchange, it is difficult to interpret why in our TA-TMA cohort HLA-DRB1*11 carriers displayed a significantly better survival. The survival difference in our cohort cannot be explained by the unequal distribution of the donor type, giving the generally worse outcome of unrelated transplantations, which were overrepresented in HLA-DRB1*11-positive cases. As the development of organ damage was comparable in HLA-DRB1*11-positive and -negative TA-TMA cases, the presence or absence of organ involvement cannot explain our observation either. The exact mechanism is yet to be explored.
In summary, our observations suggest that carriership of HLA-DRB1*11 predisposes for the manifestation of TA-TMA and favourably influences the survival of TA-TMA affected individuals in a single centre cohort of 425 adult patients. However, because of the limitations of a retrospective data process, these results should be confirmed by reanalysis of previously published TA-TMA cohorts, and furthermore in a large prospective cohort. Further studies should address whether response to treatment modalities differs in HLA-DRB1*11 carriers and non-carriers.
